U.S. STOCKS ON THE MOVE-Synopsys, Cboe, GameStop
Celcuity gains as breast cancer drug launches in US
U.S. STOCKS ON THE MOVE -Nebius, Securitize, Viant Technology
U.S. STOCKS ON THE MOVE -GlobalFoundries, Lucid, Phillips 66
U.S. STOCKS ON THE MOVE-Generac, Jefferies, Applied Digital
Celcuity gains; J.P.Morgan initiates coverage with 'overweight'
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
U.S. RESEARCH ROUNDUP-Cisco, Fox Corp, Target
Celcuity Inc. reports results for the quarter ended June 30 - Earnings Summary
Celcuity posts narrower-than-expected loss as R&D costs decreased
Brief: Celcuity Q2 Adjusted EPS USD -1.07 Vs. IBES Estimate USD -1.16
Brief: Newly FDA-Approved Revtorpyk™ (Gedatolisib) Included In The National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines For Hr+/Her2- Locally Advanced Or Metastatic Breast Cancer
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
Celcuity falls as delayed launch of breast cancer drug overshadows first FDA approval
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug (updated)
U.S. STOCKS ON THE MOVE-Merck, Alibaba, BlackRock
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Celcuity falls as delayed launch of breast cancer drug overshadows first FDA approval